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Background  
Randomized clinical trials (RCTs) have revolutionized modern cardiovascular therapy. They 
are now the gold standard to prove efficacy of new treatment modalities with drugs, devices, 
surgery, and other interventions. Moreover, by allowing for the play of chance, RCTs also 
provide important information on safety and tolerability of a treatment. Furthermore, the 
randomization procedure eliminates both known and unknown confounders. This opens the 
opportunity to prove causality of an intervention for outcome.1 
Trialists try to do their best to provide utmost quality of all aspects of RCTs. After completing a 
trial, we often hear that many lessons had to be learned from the respective trial and that the 
next trial should take this gain in knowledge into account.  
With a series of three review articles, the authors aim to focus on critical methodological 
aspects of RCTs. This article focuses on endpoints and will be followed by a second article on 
rules to stop trials, and a third one will deal with subgroup analysis. According to the specificity 
of our Journal, we specially look at trials on cardiovascular drugs and will preferentially provide 
examples of metabolic interventions, e.g. by lipid lowering and hypoglycemic drugs. 
 
The case for hard endpoints 
The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. At 
the time of the establishment of the protocol for a RCT, many interests have to be taken into 
account. A clinical researcher wants to provide innovation on treatment and to have an 
opportunity for high impact publications; and the sponsor wants to demonstrate progress by a 
new treatment and to open a new market. Thus, both sides want to end up with a positive trial. 
An important step is therefore to select the appropriate endpoints. 
What is an appropriate endpoint? From a clinical standpoint it is the benefit for the patient, 
which includes survival without severe debilitating disease like stroke. In that respect, a 
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hierarchy of endpoints was proposed by J. Lubsen (adapted to Figure 1).2,3 The major 
distinction is between hard and soft endpoints.4 Some studies also consider costs. However, 
although important, this is not a medical target. After the disturbing results of Flosequinan, the 
need to include mortality as an endpoint in cardiovascular studies has become a requirement 
from the regulatory agencies (see below).5 However, more recently, regulatory agencies have 
become more open to include benefits other than mortality in the approval of new drugs. Major, 
well-defined morbidity endpoints like myocardial infarction (MI) and stroke are examples. 
Furthermore, with the reduction of cardiovascular mortality because of the effective treatments 
proven in the past decades, also hospitalization for cardiac causes has become a relevant 
end-point. 
Hierarchy of endpoints 
Efficacy endpoints must be clinically relevant and can be hierarchically divided into three 
groups.   Group 1: all cause mortality, cardiovascular mortality, non-cardiovascular mortality; 
Group 2: morbidity i.e. MI, stroke, hospitalization for cardiac causes, and revascularization; 
and Group 3: surrogate endpoints, effects on quality of life, and posthoc endpoints (Figure 1).6 
Mortality endpoints 
The hardest endpoint level is mortality. “Dead or alive” is a clear and easily recordable natural 
endpoint. It becomes more difficult to prove the cause of death. When considering 
cardiovascular endpoints, deaths from well-documented MI or stroke (with imaging proof) are 
highly trustable. Moreover, unwitnessed sudden death is also often due to MI or stroke; 
however, pulmonary embolism, primary ventricular fibrillation, aortic rupture are rarely proven 
or disproven to be the cause of death and nevertheless often figure under cardiovascular 
death.7 
Beyond any doubt is all-cause mortality. It is the holy grail of endpoints reflecting a net benefit 
with regard to fatal events. Yet, it is clear that all-cause mortality by itself is a composite 
endpoint. Traditionally, mortality has been sub-categorized into cardiovascular versus non-
cardiovascular. As a rule, e.g. in lipid interventions, cardiovascular but not non-cardiovascular 
mortality was reduced, but it was essential to demonstrate that the non-cardiovascular 
mortality was not increased as it may reflect fatal adverse effects (e.g. death from cancer).  
This “dogma” was recently broken by the ODYSSEY OUTCOMES trial,8 where it was shown  
that also non-cardiovascular deaths were reduced in the intervention group in parallel with  
cardiovascular deaths.1  
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Although all-cause mortality should be the preferred mortality endpoint in cardiovascular 
studies, both all-cause death and cause-specific death must be assessed and reported.  
Cardiovascular death may represent an adequate endpoint providing that the therapeutic effect 
on all-cause mortality is at least neutral. In other words, some excess in non-cardiovascular 
mortality can be acceptable if the all-cause mortality is reduced. It is always of pivotal 
importance to define the mode of cardiac death and a central adjudication of the causes of 
death may be warranted. 
Composite endpoints 
In RCTs of cardiovascular pharmacotherapy, primary endpoints include major adverse 
cardiovascular events (MACE, classically a 3-point MACE, i.e. the total of cardiovascular 
death, non-fatal stroke and non-fatal MI); hospitalization for cardiac causes is frequently added 
(e.g. in heart failure studies).  Composite endpoints are commonly used in order to reduce the 
sample size or duration of the study, especially when a low event rate is expected. These 
endpoints are acceptable but must include mortality. The disadvantage of broader composite 
endpoints which include softer endpoints should be considered because softer endpoints may 
dilute the contrast between groups.9 
Thus, a legitimate way towards a positive trial outcome is to test for composite endpoints, 
particularly if the segments considered are of the same cause like the atherosclerosis-related 
endpoints stroke, MI, and cardiovascular deaths.9 Such an approach is particularly useful if the 
trial tests a more intensive versus a standard regimen, and not an intervention versus placebo. 
Survival studies using positive control drug(s) may be acceptable but should be limited to drugs 
that have consistently shown efficacy on survival, as it has been the case for statins in the 
past. Examples are PROVE-IT10 and IMPROVE-IT.11  
As to death, either all-cause mortality or cardiovascular mortality are useful as part of the 
composite endpoint. For the reasons outlined above, all-cause mortality appears preferable. 
The objective then is to increase survival without MI or stroke, an outcome that is well accepted 
in the broad public. 
Non-Fatal endpoints  
Among non-fatal events, it is mandatory to distinguish between natural events (e.g. MI or  
stroke) and physician-driven events like revascularization procedures.12 The former represent  
the natural progression of disease similarly to mortality and can be proven by ECG/troponins  
or imaging, respectively. The latter are open to judgement of the clinician for indication and  
therefore less objective. Revascularization should be regarded as a soft endpoint.  
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Nevertheless, the category of revascularization is often necessary e.g. in peripheral artery  
disease trials to end up with a significant result. If it is the only one, the outcome of the trial is  
debatable. If revascularization is embedded in hard endpoints like in FOURIER13 it makes trials  
earlier positive. However, revascularization endpoints can also result in confusion, see below.  
Myocardial infarction as an endpoint  
The definition of MI has changed importantly over the last decades. First, it was considered a  
myocardial necrosis that clinically was reflected as an event with acute chest pain, rise of  
creatine kinase, and typical ST elevation, an entity nowadays termed STEMI (ST elevation  
myocardial infarction). Next, it became clear that also myocardial necrosis without ST elevation  
but with other ECG changes exists, leading to the term NSTEMI (non ST elevation myocardial  
infarction). More recently, in recognition of the excellent sensitivity of new troponin assays -  
but perhaps deemphasizing specificity -, any event with elevated troponins in a clinically  
suggestive situation is classified as an MI. In this context, diagnosis of MI has become much  
more sensitive but also can represent considerably less myocardial damage, and ultimately be  
a softer endpoint.  Given the evolving definition of MI, the adjudication of this endpoint in clinical  
studies is important.14  
Unstable angina  
Among cardiovascular endpoints, a matter of debate is hospitalization due to unstable angina.  
For clinicians it is a common experience that chest pain patients often are admitted to hospital  
with the aim of not missing a severe condition. However, the diagnosis may be uncertain. In  
many trials, unstable angina emerged as a useless additional endpoint. Anyway, in the era of  
high-sensitivity troponins many formerly diagnosed cases of unstable angina nowadays will be  
NSTEMIs. In contrast, a very good example of thoroughly recording unstable angina as an  
endpoint is ODYSSEY OUTCOMES8 where it was required to go along with typical history,  
ECG changes, and contemporary evidence of coronary obstruction. In summary, however, we  
take the position to judge unstable angina not as a reliable hard endpoint.15  
A judgment of revascularization and unstable angina   
Taken together, the experience from modern cardiovascular trials rather is against including  
revascularizations or unstable angina into a composite endpoint because they do not add much  
clarity to the overall outcome and even may dilute the result. Such an experience followed the  
PROACTIVE trial16 testing pioglitazone versus a comparator regimen. The primary composite  
endpoint included revascularization operations together with death, MI, and stroke and failed  
significance. In sharp contrast, the predefined secondary endpoint of death, MI, and stroke  
without revascularization was significantly positive. The simple failure to meet the primary  
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endpoint resulted in viewing the trial as not positive. This is an example how the ambitious  
selection of endpoints to force a trial into success may end up in the opposite. A further  
example how soft endpoints in composite may lose study success by dilution is TRACER  
ACS.17 Therefore, for composite endpoints we would request to combine only hard endpoints  
like MI, stroke and death. We would discourage to impute also revascularization or unstable  
angina. Anyway, it should always be discernible what hard endpoints occurred in the study.  
There is traditional acceptance that a 3-point MACE (death, MI, or stroke) is a valid and  
meaningful composite endpoint.15  
A new paradigm: Total events  
A very interesting innovation in endpoint acquisition is the total event paradigm. Up to very  
recently, endpoints were recorded as the time that passed from the onset of study to the first  
event. With Cox regression analysis, this time to first event was the one-or-nothing parameter  
to be compared between the treatment arms. In this way, an individual patient could only score  
once in the conduct of the study. However, if this patient had a second event, the latter did not  
count. This means that multiple events in the same patient are not counted which represents  
a loss in sensitivity to distinguish outcome between treatment arms. This lack is taken into  
account by the recently more often used approach of “total events”. Composite endpoints  
including recurrent events are now becoming increasingly used in cardiovascular trials and  
can serve as primary composite endpoint. Here, with different statistical methods one counts  
also two or more events in a given individual. This concept promises to detect differences  
better between treatment arms.18  
Consistently, recurrent morbid events are becoming a popular and acceptable predefined  
endpoint in cardiovascular trials. Different methods for the analysis of recurrent event analysis  
have been proposed because they should be assessed with appropriate statistical methods.   
Usually hospitalizations for cardiac causes represent a frequent recurrent event to include in  
the analysis alongside the terminal event. Time-to-recurrent cardiovascular-related  
hospitalizations may therefore, be adjusted for correlated terminal cardiovascular (CV) events  
(all-cause death, fatal stroke, etc.). The analysis of recurrent events can be performed after  
study patients have been observed for an adequate follow-up or when an adequate number of  
adjudicated events have occurred (counting multiple events per subject).   
For example, by counting total events, IMPROVE-IT11 demonstrated superiority of the  
combination of ezetimibe 10 mg and simvastatin 40 mg daily versus simvastatin 40 mg alone,  
which was more pronounced in the recurrent events analysis than in the classical Cox  
regression approach. Similar results are reported from ODYSSEY OUTCOMES19 and very  
recently from REDUCE-IT20. Thus, total events recording is a valuable way to prove benefit of  
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an innovation, particularly if a more intense intervention is compared to a standard one. The  
“total endpoint burden” is very important for the patient as well as for the health-care system.  
Because it is so logical to record total events, we cannot see any reason why it should not  
become a primary strategy in all RCTs. One disadvantage of the total events approach may  
be that a patient with multiple events is weighted higher than one with only a single event. Of  
course, no advantage is offered by the total events` analysis if the first event is a fatal one.  
Surrogate markers  
By definition, surrogate parameters are not endpoints but rather risk factors (like LDL  
cholesterol or HbA1c) or imaging measures (like plaques in carotid ultrasound or coronary  
calcium in computerized tomography). In phase III outcome trials, surrogates cannot be  
accepted as endpoints. In contrast, information from phase II trials can be very useful for the  
conception of a RCT. For example, the intense reduction of LDL cholesterol seen with PCSK9  
antibodies in phase II trials had an important impact on the planning of RCT duration, dosage  
and on other considerations in the RCTs. Weintraub, Lüscher and Pocock in an excellent  
review21 came to the conclusion that with surrogates there is some peril and that not all  
surrogates are equally bad. To become valid, a surrogate should provide a strong association  
with outcome measures, consistent evidence from different trials, a significant correlation with  
endpoints in each trial, and a close link to endpoints. Moreover, the type of population of the  
particular RCT should be taken into account21.   
An important aspect of the quality of a surrogate is causality. A positive example is LDL  
cholesterol where we have a strong impression of causality from epidemiology, mendelian  
randomization and intervention studies22. In contrast, glycemic interventions in diabetes  
mellitus - which is a strong risk factor for cardiovascular disease – failed to predict outcome  
measures. Even more surprising, RCT`s demonstrated that outcome can be significantly  
improved by SGLT2 inhibitors23–25 and some GLP1 receptor agonists without lowering blood  
glucose importantly more than in the comparator arms.26–28 Although hyperglycemia is the  
established cause of microangiopathy, such a connection of glucose with macroangiopahy is  
less clear; this can explain the observed results above. Probably in future high-dimensional  
biological data, including data from gene expression could be used as new useful surrogate  
markers.   
Adjudication of endpoints  
A further discussion relates to adjudication of endpoints. Adjudication by a blinded external  
panel indicates some arbitrary element in the way to arrive at uniformity in diagnosis of a  
clinical entity that counts as an event. The issue is particularly relevant, for example, in the era  
of troponin or biomarker elevations as criteria for infarction, where precise interpretations,  
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especially in timing with regard to peri-interventional findings may vary between sites.  
Adjudication is a tedious and expensive process. In most trials, adjudication confirms most of 
the investigator-reported events. The COMPASS trial piloted a semi-automated system which 
reduced the need for manual adjudication by some 40%.29 
Net benefit 
Whenever an intervention has an intrinsic risk for harm like antithrombotic therapy, the concept 
of net benefit is an important endpoint. Net benefit is e.g. reduction of MI or stroke minus the 
increase of bleed. The latter then usually is semi-quantitatively assessed as major or minor 
and specified for regions, like gastrointestinal versus intracranial bleed in the trials of 
NOAC`s.30 The severity and clinical importance of the good event versus the severity and 
clinical importance of the bad event can importantly influence this net benefit.  
Loss of follow-up 
Loss to follow-up is a meaningful number in outcome evaluation. The lower it is, the better. 
However, whether the loss favors an overestimation or an underestimation of results is difficult 
to assess.31 
Predefined versus post-hoc endpoints.  
The gold standard in RCTs must be a predefined primary endpoint, regardless if it is a single 
or a composite one. Consistently, also if a secondary endpoint is chosen, it has to be 
predefined. In a strict evidence-based sense, no post-hoc endpoints are acceptable. However, 
reality can require post-hoc analyses if they appear beneficial for medical patient-related 
reasons. One example is that CANVAS, a trial with the SGLT2 inhibitor canagliflozin, reported 
increased amputation rates in the verum group.24 Therefore post-hoc analysis of this endpoint 
appeared mandatory in the other two trials of SGLT2 inhibitors, EMPAREG OUTCOME23 and 
DECLARE25, in order to find the truth. No evidence for this problem arose which underlined 
the predefined favorable safety outcome in those studies. In positive contrast, the findings of 
reduced hospitalization rates for heart failure under SGLT2 inhibitors prompted a post-hoc look 
into ejection fraction findings in those studies. 
Regulatory aspects of approval 
Clinical trials have shown that LDL-lowering therapy with HMG-CoA reductase inhibitors 
reduces the risk for coronary heart disease (CHD) and that the relationship between LDL-C 
levels and CHD risk is consistent over a broad range of LDL levels. Furthermore, there is not 
a clear cut off to define "normo-cholesterolemia" and "hyper-cholesterolemia". Indeed, 
epidemiologic data indicate that for a given level of cholesterol, the cardiovascular risk 
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increases according to the associated risk factors. Other lipid disorders such as  
hypertriglyceridemia may be present in patients with elevated cholesterol levels (“mixed  
hyperlipidemia”) or may be isolated or associated with low high density lipoprotein cholesterol  
(HDL-C) (atherogenic dyslipidaemia, high non-HDL-C).32   
   
Type 2 diabetes is a cardiovascular equivalent and it is a complex disorder which involves  
various degrees of decreased beta-cell function and peripheral insulin resistance. Glucose  
control in patients with type 2 diabetes mellitus deteriorates progressively over time, and, on  
average requires a new intervention with glucose-lowering agents every 3-4 years in order to  
obtain/retain good control. However, there are conflicting data on whether glucose control  
assessed a by HbA1c is an adequate marker of efficacy.  Indeed, in the past decades studies  
aimed at tight glucose control have failed to demonstrate benefit. Some glucose lowering drugs  
are associated with increased risk of cardiovascular events and for this reason the regulatory  
agencies (EMA, FDA) require mortality/morbidity studies to demonstrate the safety of new  
glucose lowering agents. These studies can be conducted as post-marketing commitment in  
Europe. More recently, however, newer glucose lowering drugs have shown to reduce  
cardiovascular events and mortality in diabetic patients.33 This opens the question on future  
drug development of glucose lowering drugs.   
  
For the approval of new drugs for the treatment of lipid disorders and diabetes mellitus,  
demonstration of efficacy on lipid levels and glucose control respectively are required. These  
data are usually required from short-term studies and longer-term studies are required to  
demonstrate safety. Furthermore, the demonstration of an effect on clinical outcomes is of  
pivotal importance for drugs acting on lipid metabolism and will be also central in the  
development of glucose lowering drugs.  
A relative reduction in LDL-C level is an adequate primary efficacy endpoint in patients with  
primary hypercholesterolemia, provided that claims in the label are restricted to a lipid lowering  
effect. An isolated effect on TG or HDL-cholesterol is not an adequate proof of efficacy for new  
lipid-modifying agent. The effect should be contextualised in conjunction with the effect on non- 
HDL cholesterol. The preferred primary endpoint to show a beneficial effect of cardiovascular  
end points should be a composite of major cardiovascular events (CV or all-cause death, non- 
fatal myocardial infarction and non-fatal stroke). These events should be adjudicated by a  
blinded, independent committee. If cardiovascular instead of all-cause mortality is used as  
primary endpoint, the effect of the new treatment on non-cardiovascular mortality should also  
be evaluated.34,35 The inclusion of other events, such as transient ischemic attack, silent MI,  
unstable angina pectoris or therapeutic interventions (need for PCI (Percutaneous Coronary  
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Intervention)) can be used to increase statistical efficiency and therefore, reduce the sample 
size and/or trial duration. 
In the past, cardiovascular safety had not been systematically assessed in the context of the 
clinical development of glucose lowering agents. After the withdrawal from the EU market of 
rosiglitazone, both EMA and FDA have requested that the development programme of 
glucose-lowering medications should provide sufficient information supporting the lack of a 
drug-induced excess cardiovascular risk. The emphasis of the safety studies should be on 
major cardiovascular events, CV death, non-fatal myocardial infarction and stroke, but 
hospitalisation for unstable angina could also be included in a composite endpoint if the main 
objective is to exclude a macrovascular safety signal. Events such as revascularization and/or 
worsening of heart failure should also be evaluated as appropriate according to the drug profile.  
Insights from RCTs in peripheral artery disease into endpoints.   
In studies also including peripheral artery disease patients, additional endpoints arising from  
the lower extremities are important. Major adverse limb events (MALE) refer acute  
complications in the limb: and are defined as acute limb ischemia, major amputation, or urgent  
revascuarization13. Among these, revascularizations are the most frequent entity, including  
both surgery and transluminal interventions. Similar to what was summarized above on  
coronary revascularizations, these procedures are not considered hard endpoints. In contrast,  
major or minor amputations are harder endpoints. FOURIER36 showed for the first time that a  
reduction in MALE is brought about by robust LDL-C lowering. Future RCTs of lipid and  
diabetes therapy should consider MALE as important endpoints.  
Endpoints selection in observational studies   
All the rules outlined above should also be applied for observational studies. Here, we  
particularly emphasize the issue of total events again. Both, statistical power and robustness  
of data benefit from that approach, two reasons for frequently encountered limitations of  
negative findings in observational studies.37  
Hierarchical testing  
A further point is the recent introduction of hierarchical testing of predefined endpoints. In an  
attempt to avoid multiple testing, it is considered fair not to use every endpoint separately.  
Recent examples include the ARISTOTLE trial of antithrombotics38 and, more recently  
ODYSSEY OUTCOMES.8 The finding of a reduction of all-cause mortality was published as  
an only “nominal significance”. The ambiguous reception in the scientific community  
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demonstrated that the sacrifice of the clinically most important endpoint (see above) simply for  
statistical purity is still a matter of debate.  
Questionnaires and quality of life assessment  
Although well-being is of utmost importance for the patient, e.g. with heart failure or diabetes  
mellitus, this type of endpoint is soft and lacks objective measures. The perception of well- 
being by the patient is open for personal bias. Thus, quality of life is only rarely included in  
RCTs of cardiovascular drugs.39  
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